- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12:46 | Hemab collects another $157M to go after 'underserved' blood diseases | ||
| 12:46 | Community pharmacies and BioPharma: Advancing whole-patient care together | ||
| 00:46 | Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease | ||
| Fr | Biogen licenses a possible immune drug from OrbiMed-backed biotech | ||
| Fr | Adverum, hammered by gene therapy downturn, sells to Lilly in unusual deal | ||
| Fr | Sanofi says 'soft' start to fall immunizations slowed vaccine sales | ||
| Fr | Chugai buys a kidney biotech; ICER targets rising launch prices | ||
| Fr | FDA clears return of GSK's once-withdrawn multiple myeloma drug | ||
| Do | Ventyx shares soar after study suggests cardiovascular benefits for experimental drug | ||
| Mi | Sanofi drug acquired in buyout succeeds in rare disease trial | ||
| Mi | Alkermes expands sleep portfolio with acquisition worth up to $2.1B | ||
| Mi | Alector dementia drug, partnered with GSK, fails in key study | ||
| Mi | Takeda stakes more than $11B on cancer drugs from China | ||
| Mi | Electra nabs $183M for its rare disease drug ambitions | ||
| Mi | Flagship bets again on AI with Expedition | ||
| Di | Novo's main shareholder pushes out more than half of company's board | ||
| Di | Iambic partners with Jazz Pharmaceuticals; Merck breaks ground on $3B plant | ||
| Di | Galapagos to wind down cell therapy business after failed attempt at sale | ||
| 20.10. | Alto shares double on plans to speed depression drug's development | ||
| 20.10. | Mark Cuban says Cost Plus Drugs will partner with TrumpRx | ||
| 20.10. | AstraZeneca, Daiichi's Datroway excels in hard-to-treat breast cancer | ||
| 20.10. | Summit's dual-acting drug scores lung cancer win | ||
| 20.10. | Exelixis shares dip on colorectal cancer data | ||
| 20.10. | From weeks to minutes: How generative AI transforms pharma data and ROI | ||
| 20.10. | The self-perform edge: Fast, reliable construction for life sciences facilities |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .